Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate, phosphate (1:1) | 85880-75-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - Eburnan型生物碱
• 英文名称: Ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate, phosphate (1:1)
• 英文别名: ethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate;phosphoric acid
• CAS: 85880-75-7
• 化学式: C22H29N2O6P
• 分子量: 448.4
• InChiKey: MLLIRSFOVUKPLI-LBPAWUGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.22
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• APOVINCAMINIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME
  申请人：Hidaka, Hiroyoshi

  公开号：EP0864571A1

  公开（公告）日：1998-09-16

  This invention relates to an apovincaminic acid derivative represented by the following formula (1): wherein R1 represents a lower alkyl group, and R2 represents an aryl group, which may be substituted by 1 to 5 substituents selected from halogen atoms and lower alkyl, lower alkoxy, lower alkoxycarbonyl, acylamino and nitro groups, a benzyl group, a quinolyl group or a thienyl group, or an acid addition salt thereof; and also to a drug containing the same. This compound has excellent vasodilating activity and platelet aggregation inhibiting activity, and can be used for the treatment of cerebrovascular disorder, thromboembolism and chronic arterial occlusive diseases and also for the improvement of blood flow disturbances.

  本发明涉及一种由以下式（1）表示的apovincaminic酸衍生物：其中R1表示较低的烷基团，R2表示芳基团，该芳基团可被1至5个取代基所取代，所述取代基选自卤素原子和较低的烷基、较低的烷氧基、较低的烷氧羰基、酰胺基和硝基团，苯甲基团，喹啉基团或噻吩基团，或其酸加成盐；同时也涉及一种含有该化合物的药物。该化合物具有出色的血管扩张活性和抑制血小板聚集活性，可用于治疗脑血管疾病、血栓栓塞和慢性动脉闭塞性疾病，也可用于改善血流障碍。
• NOVEL COMPOSITION STIMULATING THE CEREBRAL ACTIVITY AND BASED ON ALCALOIDS HAVING AN EBURNAMENINE NUCLEUS, AND PREPARATION METHODS
  申请人：Decox, S.L.

  公开号：EP0760240A1

  公开（公告）日：1997-03-05

  The present invention is based on the discovery of the potent action that certain alcaloids with an eburnamenine nucleus have when they are administered in association with compounds having a xantine structure. A synergic potent action in the cognoscitive capacity is obtained and, consequently the cerebral activity is reinforced in general in the short and long term following the oral administration of the patented composition. The disclosed composition contains quantities comprised between 0.5 and 10 mg of alcaloids or extract of alcaloids of the eburnamenine type per 100 ml of beverage of cola, lemon, cocoa, ginseng, tonic water, coffee or any other beverage obtained from extracts, in quantities comprised between 0.4 and 30 mg of alcaloids or extracts, of alcaloids of the eburnamenine type per each 5-20 g of dry, semi-dry or wet extract of coffee, cola, cocoa, tea, ginseng, tonic water or any other extract for beverages.

  本发明的基础是发现了某些具有 eburnamenine 核的生物碱在与具有 xantine 结构的化合物一起服用时具有的强效作用。在口服本专利组合物后，可在认知能力方面获得协同的强效作用，从而在短期和长期内普遍增强大脑活动。在每 100 毫升可乐、柠檬、可可、人参、汤力水、咖啡或任何其他从提取物中提取的饮料中，本专利组合物含有 0.5 至 10 毫克的生物碱或 eburnamenine 类生物碱提取物，含量在 0.4 至 30 毫克之间。每 5-20 克咖啡、可乐、可可、茶、人参、汤力水或任何其他饮料的干提取物、半 干提取物或湿提取物中含有 4 至 30 毫克 eburnamenine 类生物碱或提取物。
• Citrate de vinpocetine et son procédé de préparation
  申请人：COVEX (S.A.)

  公开号：EP0154756B2

  公开（公告）日：1996-10-23
• US4749707A
  申请人：——

  公开号：US4749707A

  公开（公告）日：1988-06-07
• US6290994B1
  申请人：——

  公开号：US6290994B1

  公开（公告）日：2001-09-18